BACKGROUND: & AIMS: The effects of n-3 LC-PUFA-supplemented dairy products on cardiovascular risk factors in mildly hypertriacylglycerolemic patients (TAG: ≥1.5 mmol/L) were determined. METHODS:Fifty-one patients (25 f, 26 m) were included in the double-blind, placebo-controlled cross-over study and were randomly divided into two groups. Both groups received intervention (3g n-3 LC-PUFA/d) and control dairy products consecutively for fifteen weeks with a ten-week wash-out phase between the two treatments. Blood samples and 24-h urine were obtained at the beginning and at the end of each period. The blood lipids were determined by enzymatic methods and using the autoanalyser Synchron LX systems (Beckman Coulter). 7,8-Dihydro-8-oxo-2'-deoxyguanosine and fatty acids were analysed with HPLC and GC. RESULTS: Generally, the consumption of the intervention products resulted in a significant improvement of cardiovascular risk factors, e.g., n-3 FA index, AA/EPA ratio, total cholesterol, and TAG. The TAG and LDL/HDL ratio were lower at the end of the intervention period in comparison with the control period, whereas HDL cholesterol was higher at the end of the intervention period. Further, n-3 LC-PUFA-enriched products did not cause additional oxidative DNA damage as shown by the 7,8-dihydro-8-oxo-2'-deoxyguanosine excretion. CONCLUSIONS: The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors.
RCT Entities:
BACKGROUND: & AIMS: The effects of n-3 LC-PUFA-supplemented dairy products on cardiovascular risk factors in mildly hypertriacylglycerolemic patients (TAG: ≥1.5 mmol/L) were determined. METHODS: Fifty-one patients (25 f, 26 m) were included in the double-blind, placebo-controlled cross-over study and were randomly divided into two groups. Both groups received intervention (3g n-3 LC-PUFA/d) and control dairy products consecutively for fifteen weeks with a ten-week wash-out phase between the two treatments. Blood samples and 24-h urine were obtained at the beginning and at the end of each period. The blood lipids were determined by enzymatic methods and using the autoanalyser Synchron LX systems (Beckman Coulter). 7,8-Dihydro-8-oxo-2'-deoxyguanosine and fatty acids were analysed with HPLC and GC. RESULTS: Generally, the consumption of the intervention products resulted in a significant improvement of cardiovascular risk factors, e.g., n-3 FA index, AA/EPA ratio, total cholesterol, and TAG. The TAG and LDL/HDL ratio were lower at the end of the intervention period in comparison with the control period, whereas HDL cholesterol was higher at the end of the intervention period. Further, n-3 LC-PUFA-enriched products did not cause additional oxidative DNA damage as shown by the 7,8-dihydro-8-oxo-2'-deoxyguanosine excretion. CONCLUSIONS: The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors.
Authors: María J Soto-Méndez; Oscar D Rangel-Huerta; María D Ruiz-López; Emilio Martínez de Victoria; Augusto Anguita-Ruiz; Angel Gil Journal: Adv Nutr Date: 2019-05-01 Impact factor: 8.701
Authors: Maria D Mesa; Josune Olza; Carolina Gonzalez-Anton; Concepcion M Aguilera; Rosario Moreno-Torres; Africa Jimenez; Antonio Perez de la Cruz; Azahara I Ruperez; Angel Gil Journal: Oxid Med Cell Longev Date: 2015-12-01 Impact factor: 6.543
Authors: Dominika Maciejewska; Małgorzata Michalczyk; Maja Czerwińska-Rogowska; Marcin Banaszczak; Karina Ryterska; Karolina Jakubczyk; Jakub Piotrwski; Joanna Hołowko; Arleta Drozd; Paweł Wysokińki; Krzysztof Ficek; Krzysztof Wilk; Anna Lubkowska; Paweł Cięszczyk; Jerzy Bertrand; Ewa Stachowska Journal: J Hum Kinet Date: 2017-12-28 Impact factor: 2.193